Recruiting location in the Saskatchewan:
ID Number: NCT02773524
Description: This study is looking to determine if regorafenib improves survival in patients with advanced gastro-oesophageal carcinoma.
Intervention: Regorafenib is a targeted chemotherapy drug that is a tyrosine kinase inhibitor. It slows down or stops the growth of cancer cells.
Can I consider participating?